VDAC1 and lung cancer: Indeed, we have demonstrated that silencing VDAC1 expression using VDAC-specific siRNA reduced cellular ATP levels and cell proliferation, and in mouse models of glioblastoma, and cervical and lung cancers, it induced metabolic reprograming, inhibited tumor development and growth and angiogenesis, and altered the tumor microenvironment [32,36,37,38,39,40,41].